Prostate Conditions Education Council (PCEC) Commend the FDA for Approving Xtandi (MDV3100)

September 6, 2012 by  
Filed under Prostate Cancer News

Xtandi has now being approved officially by the Food and Drug Administration (FDA) as reliable treatment for advanced prostate cancer.

Earlier in Clinical Trials, the makers of Xtandi revealed that this drug has shown great potency in extending the lives of men who are living with advanced prostate cancer.

The PCEC is a leading cancer group and since it commends the authorities for the approval of this drug, which can work effectively after other important therapies have failed.

The following is an extract about the PCEC’s commendations you will find as an interesting reading:

Leading prostate cancer group, the Prostate Conditions Education Council (PCEC), applauds today’s approval by the United States Food and Drug Administration (FDA) of a groundbreaking new therapy, Xtandi, formerly known as MDV3100. The drug has shown promise in clinical trials, extending the life of men with advanced prostate cancer even following other treatments.

“This new therapy represents an important advancement in the treatment of prostate cancer, extending survival in patients who failed previous chemotherapy for castration-resistant disease,” said Daniel Petrylak, M.D., PCEC council member and director of the genitourinary oncology program and co-director of the signal transduction program at the Yale University Cancer Center.

The PCEC, a national organization committed to men’s health and a leader in supporting prostate cancer research and treatment, has been working for several decades to improve treatment options.  New treatments like Xtandi – an antiandrogen therapy that acts to block testosterone, slowing prostate cancer growth – are bringing new hope to men with prostate cancer.

“Since our work with antiandrogens began over two decades ago, we have been waiting for a superior agent that shows promise for late-stage patients; we have it with the approval of Xtandi,” said E. David Crawford, M.D. head of the urologic oncology department at the University of Colorado Health Sciences Center, and founder/chairman of the PCEC.  “I am confident that this is only the beginning of success stories with this agent and that it will be used in earlier stages of prostate cancer in the near future. While this therapy is an innovative development for patients in the late stages of prostate cancer, early detection and treatment are key to survival. Continued efforts to improve awareness and education of the disease are still very important and support efforts to diagnose and treat the disease before it reaches the advance stages.”

Prostate cancer remains the second leading cause of cancer death among American men[i], and can be an aggressive disease that is most successfully treated when detected early on. Each year, the PCEC holds Prostate Cancer Awareness Week, dedicated to offering free or low-cost screenings for more than 125,000 men across the U.S. and internationally. This year, the week is being held September 16-22. Since the first PCAW in 1989, the program has helped to screen nearly five million men in the U.S., and this number continues to grow each year both at home and internationally. Click here to learn more the Prostate Conditions Education Council.

It is indeed good news that the Food and Drug Administration (FDA) has approved Xtandi. There is nothing like getting positive response for hard work.

The manufacturers of Xtandi can raise their shoulders since they have been approved. This means they have a contributed in no small manner to save the lives of thousands of men out there who may die from advanced prostate cancer.

The Prostate Conditions Education Council applauds the efforts of the FDA and another important battle won against cancer of the prostate.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. Enzalutamide (MDV3100) – a New Drug from Medivation, can Increase Lifespan for Men with Terminal Prostate Cancer
  2. Denosumab Disapproved by FDA as Metastases Prostate Cancer Drug
  3. Prostate Cancer is BETTER Than Many Other Conditions
  4. Prostrate Cancer More Conditions Symptoms
  5. Colon and Prostate Cancer – The Relationship Between The Two Conditions
  6. Education Prostrate Cancer – Prostate Cancer and Educational Program

Speak Your Mind

Tell us what you're thinking... !